Erasca (ERAS) Research & Development (2020 - 2026)
Erasca's (ERAS) quarterly Research & Development came in at $27.3 million in Q1 2026, up 4.99% YoY from $26.0 million in Q1 2025, and up 17.31% on a QoQ basis from $23.2 million in Q4 2025.
Analysis
Erasca (ERAS) Research & Development (2020 - 2026) Analysis & Trends
Erasca (ERAS) has 7 years of Research & Development data on file, last reported at $27.3 million in Q1 2026.
- Quarterly Research & Development rose 4.99% year-over-year to $27.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $94.1 million (down 16.5% YoY) and the FY2025 annual result came in at $92.9 million, down 19.51% from the prior year.
- Research & Development advanced to $27.3 million in Q1 2026, from $23.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $33.0 million in Q2 2024 to a low of $21.2 million in Q2 2025.
- A 5-year average of $26.6 million and a median of $27.3 million in 2026 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2022 — Research & Development jumped 124.0% — and 2025, when it plunged 35.91%.
- Tracing ERAS's Research & Development over 5 years: stood at $29.4 million in 2022, then declined by 15.5% to $24.8 million in 2023, then gained by 5.31% to $26.1 million in 2024, then fell by 11.03% to $23.2 million in 2025, then grew by 17.31% to $27.3 million in 2026.
- The last three Research & Development figures came in at $27.3 million (Q1 2026), $23.2 million (Q4 2025), and $22.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | -486.00 Mn |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | 394.92 Mn |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | 612.28 Mn |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | 413.13 Mn |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 97.90 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 210.03 Mn |
| 10 | Erasca | 5.03 Bn | 5.03 Bn | - | 35.90 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 35.90 Mn |
| Mar 31, 2026 | 27.27 Mn |
| Dec 31, 2025 | 23.24 Mn |
| Sep 30, 2025 | 22.47 Mn |
| Jun 30, 2025 | 21.17 Mn |
| Mar 31, 2025 | 25.97 Mn |
| Dec 31, 2024 | 26.12 Mn |
| Sep 30, 2024 | 27.63 Mn |
| Jun 30, 2024 | 33.03 Mn |
| Mar 31, 2024 | 28.57 Mn |
| Dec 31, 2023 | 24.81 Mn |
| Sep 30, 2023 | 25.21 Mn |
| Jun 30, 2023 | 26.22 Mn |
| Mar 31, 2023 | 27.59 Mn |
| Dec 31, 2022 | 29.36 Mn |
| Sep 30, 2022 | 28.18 Mn |
| Jun 30, 2022 | 27.49 Mn |
| Mar 31, 2022 | 27.43 Mn |
| Dec 31, 2021 | 24.13 Mn |
| Sep 30, 2021 | 19.95 Mn |